<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35700481</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-6080</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Transplantation</Title><ISOAbbreviation>Transplantation</ISOAbbreviation></Journal><ArticleTitle>Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge.</ArticleTitle><Pagination><StartPage>1528</StartPage><EndPage>1537</EndPage><MedlinePgn>1528-1537</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TP.0000000000004200</ELocationID><Abstract><AbstractText>Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over the past 12-18 mo, most notably in early outpatient therapy. In most cases, solid organ transplant recipients were not included in the original clinical trials of these agents, so studies of real-world outcomes have been important in building our understanding of their utility. This review examines what is known about clinical outcomes in solid organ transplant recipients with newer therapies. SARS-CoV-2 monoclonal antibodies for early treatment or prophylaxis have likely prevented many hospitalizations and deaths. In addition, convalescent plasma, the oral drugs nirmatrelvir/ritonavir and molnupiravir, remdesivir for early outpatient treatment, anti-inflammatory therapy, and investigational virus-specific T-cell therapy will be discussed. Finally, the later consequences of COVID-19, such as secondary infections, long COVID symptoms, and persistent active infection, are identified as areas for future research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avery</LastName><ForeName>Robin Kimiko</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplantation</MedlineTA><NlmUniqueID>0132144</NlmUniqueID><ISSNLinking>0041-1337</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016377" MajorTopicYN="Y">Organ Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="N">Transplant Recipients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="N">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>14</Day><Hour>16</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35700481</ArticleId><ArticleId IdType="pmc">PMC9311293</ArticleId><ArticleId IdType="doi">10.1097/TP.0000000000004200</ArticleId><ArticleId IdType="pii">00007890-202208000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Avery RK. COVID-19 therapeutics for solid organ transplant recipients; 6 months into the pandemic: where are we now? Transplantation. 2021;105:56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">33141805</ArticleId></ArticleIdList></Reference><Reference><Citation>Buehrle DJ, Sutton RR, McCann EL, et al. . A review of treatment and prevention of coronavirus disease 2019 among solid organ transplant recipients. Viruses. 2021;13:1706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8471770</ArticleId><ArticleId IdType="pubmed">34578287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz M, Aguado JM. Immunomodulatory therapies for COVID-19 in solid organ transplant recipients. Curr Transplant Rep. 2020;7:379&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581948</ArticleId><ArticleId IdType="pubmed">33110739</ArticleId></ArticleIdList></Reference><Reference><Citation>Laracy JC, Verna EC, Pereira MR. Antivirals for COVID-19 in solid organ transplant recipients. Curr Transplant Rep. 2020;7:355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575337</ArticleId><ArticleId IdType="pubmed">33101837</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldman MR, Kates OS. COVID-19 in solid organ transplant recipients: a review of the current literature. Curr Treatment Options Infect Dis. 2021:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238515</ArticleId><ArticleId IdType="pubmed">34220357</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja MA, Mendoza MA, Villavicencio A, et al. . COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2021;35:100588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666542</ArticleId><ArticleId IdType="pubmed">33246166</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health. NIH COVID-19 treatment guidelines.
Available at https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/. Accessed April 11, 2022.</Citation></Reference><Reference><Citation>World Health Organization. Therapeutics and COVID-19: living guideline.
Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2. Accessed April 19, 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35917393</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Pestana J, Cristelli MP, Foresto RD, et al. . The higher COVID-19 fatality rate among kidney transplant recipients calls for further action. Transplantation. 2022;106:908&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038247</ArticleId><ArticleId IdType="pubmed">35250005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman F, Liu STH, Taimur S, et al. . Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: experience at large transplant center in New York City. Clin Transplant. 2020;34:e14089.</Citation><ArticleIdList><ArticleId IdType="pubmed">32918761</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand A, Razonable R. COVID-19 and solid organ transplantation: role of anti-SARS-CoV-2 monoclonal antibodies. Curr Transpl Rep. 2022;9:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8760599</ArticleId><ArticleId IdType="pubmed">35070639</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration (FDA). Emergency use authorization for nirmeltravir/ritonavir.
Available at https://www.fda.gov/media/155049/download. Accessed April 19, 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). Emergency use authorization for molnupiravir.
Available at https://www.fda.gov/media/155053/download. Accessed April 19, 2022.</Citation></Reference><Reference><Citation>Gottlieb RL, Vaca CE, Paredes R, et al. ; GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan DJ, Gebo KA, Shoham S, et al. . Early outpatient treatment for COVID-19 with convalescent plasma. N Engl J Med. 2022;386:1700-1711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky BJ, Werbel WA, Avery RK, et al. . Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204&#x2013;2206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8100911</ArticleId><ArticleId IdType="pubmed">33950155</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaghan CJ, Mumford L, Curtis RMK, et al. ; NHSBT Organ and Tissue Donation and Transplantation Clinical Team. Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and Islet transplant recipients. Transplantation. 2022;106:436&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862680</ArticleId><ArticleId IdType="pubmed">34982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman JR, Wigmore SJ. Simple vaccination is not enough for the transplant recipient. Transplantation. 2022;106:447&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862673</ArticleId><ArticleId IdType="pubmed">34982757</ArticleId></ArticleIdList></Reference><Reference><Citation>Werbel WA, Boyarsky BJ, Ou MT, et al. . Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174:1330&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252023</ArticleId><ArticleId IdType="pubmed">34125572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Ferreira VH, Ku T, et al. . Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385:1244&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N, Abravanel F, Marion O, et al. . Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262620</ArticleId><ArticleId IdType="pubmed">34161700</ArticleId></ArticleIdList></Reference><Reference><Citation>Benotmane I, Gautier G, Perrin P, et al. . Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to two doses. JAMA. 2021;326:1063&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456389</ArticleId><ArticleId IdType="pubmed">34297036</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedon AT, Alejo JL, Kim JD, et al. . 6-month kinetics and durability after 3 doses of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation. 2022;106:e281&#x2013;e283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038245</ArticleId><ArticleId IdType="pubmed">35066543</ArticleId></ArticleIdList></Reference><Reference><Citation>Alejo JL, Mitchell J, Chiang TP, et al. . Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation. 2022;106:e281-e283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038245</ArticleId><ArticleId IdType="pubmed">35066543</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedon AT, Teles MS, Alejo JL, et al. . Improved antibody response after a fifth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation. 2022;106:e262&#x2013;e263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038246</ArticleId><ArticleId IdType="pubmed">35175241</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin CX, Moore LW, Anjan S, et al. . Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation. 2021;105:e265&#x2013;e266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8549120</ArticleId><ArticleId IdType="pubmed">34310531</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazuecos A, Villanego F, Zarraga S, et al. . Breakthrough infections following mRNA SARS-CoV-2 vaccination in kidney transplant recipients. Transplantation. 2022;106:1430&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213063</ArticleId><ArticleId IdType="pubmed">35384924</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D, Park YJ, Beltramello M, et al. . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand A, Lobo SA, Wolfe K, et al. . Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience. Clin Transplant. 2021;35:e14245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995073</ArticleId><ArticleId IdType="pubmed">33595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand A, Lobo SA, Wolfe K, et al. . Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation. 2021;105:e68&#x2013;e69.</Citation><ArticleIdList><ArticleId IdType="pubmed">33724242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yetmar ZA, Beam E, O&#x2019;Horo JC, et al. . Monoclonal antibody therapy for COVID-19 in solid organ transplant recipients. Open Forum Inf Dis. doi:2021;8:ofab255</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494079</ArticleId><ArticleId IdType="pubmed">34631921</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bello A, Marion O, Vellas C, et al. . Anti-SARS-CoV-2 monoclonal antibodies in solid-organ transplant patients. Transplantation. 2021;105:e146&#x2013;e147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487703</ArticleId><ArticleId IdType="pubmed">34224543</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EC, Lee JH, Loo A, et al. . Casirivimab-Imdevimab (REGN-COV2) for mild to moderate SARS-CoV-2 infection in kidney transplant recipients. Kidney Int Rep. 2021;6:2900&#x2013;2902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8418987</ArticleId><ArticleId IdType="pubmed">34514186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahearn AJ, Thin Maw T, Mehta R, et al. . A programmatic response, including bamlanivimab or casirivimab-imdevimab administration, reduces hospitalization and death in COVID-19 positive abdominal transplant recipients. Transplantation. 2022;106:e153&#x2013;e157.</Citation><ArticleIdList><ArticleId IdType="pubmed">34519680</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes G, Devresse A, Scohy A, et al. . Monoclonal antibody therapy for SARS-CoV-2 infection in kidney transplant recipients: a case series from Belgium. Transplantation. 2022;106:e107&#x2013;e108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667674</ArticleId><ArticleId IdType="pubmed">34711781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan MY, Sayegh SE, Webb HT, et al. . Bamlanivimab for mild to moderate COVID-19 in kidney transplant recipients. Kidney Int Rep. 2021;6:2468&#x2013;2471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233547</ArticleId><ArticleId IdType="pubmed">34222731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzler HL, Kuzaro HA, Serrano OK, et al. . Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients. Transpl Infect Dis. 2021;23:e13662.</Citation><ArticleIdList><ArticleId IdType="pubmed">34081820</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano C, Servais S, Bonvoisin C, et al. . Preemptive antibody therapy for vaccine breakthrough SARS-CoV-2 infection in immunocompromised patients. Transplantation. 2021;105:e282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8612847</ArticleId><ArticleId IdType="pubmed">34456266</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang AX, Busque S, Kuo J, et al. . SARS-CoV-2 neutralizing monoclonal antibodies for the treatment of COVID-19 in kidney transplant recipients. Kidney 360. 2022;3:133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967616</ArticleId><ArticleId IdType="pubmed">35368573</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrell BA, Bloch K, El Chediak A, et al. . Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022;24:e13759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646855</ArticleId><ArticleId IdType="pubmed">34787345</ArticleId></ArticleIdList></Reference><Reference><Citation>Angarone M, Kumar RN, Stosor V. Organ transplant patients, COVID-19, and neutralizing monoclonal antibodies: the glass is half full. Transpl Infect Dis. 2021;23:e13724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646454</ArticleId><ArticleId IdType="pubmed">34534401</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein EJ, Hardesty A, Vieira K, et al. . Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: efficacy, ethnic and racial disparities. Am J Transplant. 2022;22:640&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652993</ArticleId><ArticleId IdType="pubmed">34591350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueguen J, Colosio C, Del Bello A, et al. . Early administration of anti-SARS-CoV-2 monoclonal antibodies prevents severe COVID-19 in kidney transplant patients. Kid Int Rep. 2022;7:1241&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957354</ArticleId><ArticleId IdType="pubmed">35372734</ArticleId></ArticleIdList></Reference><Reference><Citation>AlKindi F, Chaaban A, Al Hakim M, et al. . Sotrovimab use for COVID-19 infection in pregnant kidney transplant recipient. Transplantation. 2022;106:e277&#x2013;e278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038235</ArticleId><ArticleId IdType="pubmed">35135972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinchera B, Buonomo AR, Scotto R, et al. . Sotrovimab in solid organ transplant patients with early mild/moderate SARS-CoV-2 infection. A single center experience. Transplantation. 2022;106:e343&#x2013;e345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213056</ArticleId><ArticleId IdType="pubmed">35349534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran W, Langlee J, Barker L, et al. . Short-term outcomes in a nurse- and nurse practitioner-led sotrovimab initiative for solid organ transplant recipients during the Omicron surge. Transplantation. [Epub ahead of print. May 27, 2022]. doi:10.1097/TP.0000000000004217</Citation><ArticleIdList><ArticleId IdType="pubmed">35675440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sait AS, Chiang TP, Marr KA, et al. . Outcomes of SOT recipients with COVID-19 in different Eras of COVID-19 therapeutics. Transplant Direct. 2022;8:e1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8710330</ArticleId><ArticleId IdType="pubmed">34966840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kates OS, Haydel BM, Florman SS, et al. ; UW COVID-19 SOT Study Team. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. 2021;73:e4090&#x2013;e4099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454362</ArticleId><ArticleId IdType="pubmed">32766815</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldman MR, Kates OS, Safa K, et al. ; UW COVID-19 SOT Study Team. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. Am J Transplant. 2022;22:279&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653312</ArticleId><ArticleId IdType="pubmed">34514710</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien MP, Forleo-Neto E, Musser BJ, et al. ; Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV antibody combination to prevent covid-19. N Engl J Med. 2021;385:1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362593</ArticleId><ArticleId IdType="pubmed">34347950</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimeglio C, Del Bello A, Chapuy-Regaud S, et al. . Casirivimab-imdevimab to prevent SARS-CoV-2 infections in solid organ transplant recipients. Transplantation. 2022;106:e275&#x2013;e276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038236</ArticleId><ArticleId IdType="pubmed">35283456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamar N, Gouin A, Izopet J. Omicron breakthrough infection in a kidney-transplant patient given pre-exposition casirivimab and imdevimab monoclonal antibodies. Transpl Infect Dis. 2022;24:e13803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115333</ArticleId><ArticleId IdType="pubmed">35202503</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Emergency use authorization for tixagevimab/cilgavimab.
Available at https://www.fda.gov/media/154701/download. Accessed April 19, 2022.</Citation></Reference><Reference><Citation>Case JB, Mackin S, Errico J, et al. . Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Biorxiv. doi:10.1101/2022.03.17.484787</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250508</ArticleId><ArticleId IdType="pubmed">35780162</ArticleId></ArticleIdList></Reference><Reference><Citation>Benotmane I, Velay A, Vargas GG, et al. . Breakthrough COVID-19 cases despite tixagevimab and cilgavimab (Evusheld) prophylaxis in kidney transplant recipients [Epub ahead of print. March 11, 2022]. Medrxiv. doi:10.1101/2022.03.19.22272575</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350296</ArticleId><ArticleId IdType="pubmed">35713984</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran W, Shah P, Barker L, et al. . COVID-19 clinical outcomes in solid organ transplant recipients during the Omicron surge. Transplantation. 2022;106:e346&#x2013;e347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213060</ArticleId><ArticleId IdType="pubmed">35404880</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomized controlled, open-label platform trial. Lancet. 2021;397:2049&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, P&#xe9;rez Marc G, Wappner D, et al. ; Fundaci&#xf3;n INFANT&#x2013;COVID-19 Group. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384:610&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Carter RE, Senefeld JW, et al. . Convalescent plasma antibody levels and the risk of death from covid-19. N Engl J Med. 2021;384:1015&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M, Nambiar A, Pandey S, et al. . Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2021;23:e13477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537112</ArticleId><ArticleId IdType="pubmed">32989856</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeem S, Gohh R, Bayliss G, et al. . Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl Infect Dis. 2021;23:e13451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460867</ArticleId><ArticleId IdType="pubmed">32815238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Kute VB, Patel HV, et al. . Feasibility of convalescent plasma therapy in kidney transplant recipients with severe COVID-19: a single-center prospective cohort study. Exp Clin Transplant. 2021;19:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">33605203</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodionov RN, Biener A, Spieth P, et al. . Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe. 2021;2:e138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009633</ArticleId><ArticleId IdType="pubmed">33817676</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristelli MP, Langhi J, Dante M, et al. . Efficacy of convalescent plasma to treat mild to moderate COVID-19 in kidney transplant patients: a propensity score matching analysis. Transplantation. 2022;106:e92-e94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667676</ArticleId><ArticleId IdType="pubmed">34581314</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Klassen SA, Ford SK, et al. . Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021;61:2503&#x2013;2511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242637</ArticleId><ArticleId IdType="pubmed">34036587</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishbane S, Hirsch JS, Nair V. Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection. Am J Kidney Dis. 2022;79:480&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754454</ArticleId><ArticleId IdType="pubmed">35032591</ArticleId></ArticleIdList></Reference><Reference><Citation>Salerno DM, Jennings DL, Lange NW, et al. . Early clinical experience with nirmeltravir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients [Epub ahead of print. March 12, 2022]. Am J Transplant. doi:10.1111/ajt.17027</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111190</ArticleId><ArticleId IdType="pubmed">35278260</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang AX, Koff A, Hao D, et al. . Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients [Epub ahead of print. February 14, 2022]. Am J Transplant. doi:10.1111/ajt.16997</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111225</ArticleId><ArticleId IdType="pubmed">35158412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, Humar A, Ison MG, et al. . AST statement on oral antiviral therapy for COVID.
Available at https://www.myast.org/sites/default/files/AST%20Statement%20on%20Oral%20Antiviral%20Therapy%20for%20COVID%20Jan%204%20%282%29.pdf. Accessed April 19, 2022.</Citation></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. ; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19&#x2014;Final report. N Engl J Med. 2020;383:1813&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19&#x2014;interim WHO Solidarity Trial results. N Engl J Med. 2021;384:497&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader F, Bouscambert-Duchamp M, Hites M, et al. . Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID- 19 (DisCoVeRy): a phase 3, randomized, controlled, open-label trial. Lancet. 2022;22:209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8439621</ArticleId><ArticleId IdType="pubmed">34534511</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibaldi BT, Wang K, Robinson ML, et al. . Real-world effectiveness of remdesivir in adults hospitalized with COVID-19: a retrospective, multicenter comparative effectiveness study [Epub ahead of print. December 15, 2021]. Clin Infect Dis. doi:10.1093/cid/ciab1035</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754724</ArticleId><ArticleId IdType="pubmed">34910128</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamsick ML, Gandhi RG, Bidell MR, et al. . Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020;31:1384&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7351006</ArticleId><ArticleId IdType="pubmed">32513665</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakare S, Gandhi C, Modi T, et al. . Safety of remdesivir in patients with acute kidney injury or CKD. Kidney Int Rep. 2021;6:206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547837</ArticleId><ArticleId IdType="pubmed">33073066</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxeda A, Arias-Cabrales C, P&#xe9;rez-S&#xe1;ez MJ, et al. . Use and safety of remdesivir in kidney transplant recipients with COVID-19. Kidney Int Rep. 2021;6:2305&#x2013;2315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8257403</ArticleId><ArticleId IdType="pubmed">34250317</ArticleId></ArticleIdList></Reference><Reference><Citation>Elec AD, Oltean M, Goldis P, et al. . COVID-19 after kidney transplantation: early outcomes and renal function following antiviral treatment. Int J Infect Dis. 2021;104:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836972</ArticleId><ArticleId IdType="pubmed">33453396</ArticleId></ArticleIdList></Reference><Reference><Citation>Estiverne C, Strohbehn IA, Mithani Z, et al. . Remdesivir in patients with estimated GFR &lt;30&#x2009;ml/min per 1.73 m2 or on renal replacement therapy. Kidney Int Rep. 2021;6:835&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7694470</ArticleId><ArticleId IdType="pubmed">33263094</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiekhani M, Shahabinezhad F, Niknam T, et al. . Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? Virol J. 2021;18:228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607221</ArticleId><ArticleId IdType="pubmed">34809657</ArticleId></ArticleIdList></Reference><Reference><Citation>Winstead RJ, Christensen J, Sterling S, et al. . Effect of remdesivir on COVID-19 PCR positivity and cycle threshold in kidney transplant recipients. Transplantology. 2021;2:291&#x2013;293.</Citation></Reference><Reference><Citation>Gordon A, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384:1491&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-S&#xe1;ez MJ, Blasco M, Redondo-Pach&#xf3;n D, et al. ; Spanish Society of Nephrology COVID-19 Group. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant. 2020;20:3182&#x2013;3190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405397</ArticleId><ArticleId IdType="pubmed">32654422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodro M, Cofan F, R&#xed;os J, et al. . Use of anti-cytokine therapy in kidney transplant recipients with COVID-19. J Clin Med. 2021;10:1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8067800</ArticleId><ArticleId IdType="pubmed">33917093</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira MR, Aversa MM, Farr MA, et al. . Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. Am J Transplant. 2020;20:3198&#x2013;3205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537322</ArticleId><ArticleId IdType="pubmed">32946668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamani AH, Alraddadi BM, Almaghrabi RS, et al. . Early use of tocilizumab in solid organ transplant recipients with COVID-19: a retrospective cohort study in Saudi Arabia. Immun Inflamm Dis. 2022;10:e587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926500</ArticleId><ArticleId IdType="pubmed">35029324</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group. Dexamethasone for hospitalized patients with COVID-19. N Engl J Med. 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Permpalung N, Bazemore K, Chiang TP, et al. . Impact of COVID-19 on lung allograft and clinical outcomes in lung transplant recipients: a case-control study. Transplantation. 2021;105:2072&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">34075005</ArticleId></ArticleIdList></Reference><Reference><Citation>Permpalung N, Chiang TP, Massie AB, et al. . Coronavirus disease 2019-associated pulmonary aspergillosis in mechanically ventilated patients. Clin Infect Dis. 2022;74:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989534</ArticleId><ArticleId IdType="pubmed">33693551</ArticleId></ArticleIdList></Reference><Reference><Citation>Clancy CJ, Nguyen MH. Coronavirus disease 2019-associated pulmonary aspergillosis: reframing the debate. Open Forum Infect Dis. 2022;9:ofac081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903513</ArticleId><ArticleId IdType="pubmed">35386295</ArticleId></ArticleIdList></Reference><Reference><Citation>Duivenvoorden R, Vart P, Noordzij M, et al. ; ERACODA Collaborators. Clinical, functional, and mental health outcomes in kidney transplant recipients 3 months after a diagnosis of COVID-19. Transplantation. 2022;106:1012&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038249</ArticleId><ArticleId IdType="pubmed">35320154</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleberg M, Niemann CU, Moestrup KS, et al. . Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222:1103&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454684</ArticleId><ArticleId IdType="pubmed">32702095</ArticleId></ArticleIdList></Reference><Reference><Citation>Malsy J, Veletzky L, Heide J, et al. . Sustained response after remdesivir and convalescent plasma therapy in a B-cell-depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73:e4020&#x2013;e4024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665388</ArticleId><ArticleId IdType="pubmed">33103195</ArticleId></ArticleIdList></Reference><Reference><Citation>Baang JH, Smith C, Mirabelli C, et al. . Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797758</ArticleId><ArticleId IdType="pubmed">33089317</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J, et al. . Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiano J, Bush R, Acharya R, et al. . Persistent viral shedding despite seroconversion in a kidney transplant recipient with severe extrapulmonary COVID-19. BMJ Case Rep. 2020;13:e239612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654101</ArticleId><ArticleId IdType="pubmed">33168542</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodore DA, Greendyke WG, Miko B, et al. . Cycle thresholds among solid organ transplant recipients testing positive for SARS-CoV-2. Transplantation. 2021;105:1445&#x2013;1448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222146</ArticleId><ArticleId IdType="pubmed">33606483</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary MC, Crain CR, Qiu X, et al. . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence characteristics of coronavirus disease 2019 (COVID-19) persistence and reinfection. Clin Infect Dis. 2022;74:237&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135388</ArticleId><ArticleId IdType="pubmed">33906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liroff K, Fleury C, Dumitrescu C, et al. . Delayed onset of COVID-19 in an immunosuppressed patient. Infect Dis Clin Pract (Baltim Md). 2021;29:e448&#x2013;e450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8594382</ArticleId><ArticleId IdType="pubmed">34803351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaila V, Sirkeoja S, Blomqvist S, et al. . SARS-CoV-2 late shedding may be infectious between immunocompromised hosts. Infect Dis (Lond). 2021;53:880&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220436</ArticleId><ArticleId IdType="pubmed">34137349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP, et al. ; CITIID-NIHR BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Pouderoux C, P&#xe9;r&#xe9; H, et al. . Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136:2290&#x2013;2295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7702482</ArticleId><ArticleId IdType="pubmed">32959052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Godron AS, Lanoy E, et al. . Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia. 2022;36:1025&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805670</ArticleId><ArticleId IdType="pubmed">35105946</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti MV, Gaston DC, Morris CP, et al. . Combination therapy with casirivimab/imdevimab and remdesivir for protracted SARS-CoV-2 infection in B-cell-depleted patients [Epub ahead of print. November 3, 2021]. Open Forum Infect Dis. doi: 10.3389/fimmu.2021.763412</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9154336</ArticleId><ArticleId IdType="pubmed">35663288</ArticleId></ArticleIdList></Reference><Reference><Citation>Martits-Chalangari K, Spac CW, Askar M, et al. . ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2&#x2013;specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: case report. Am J Transpl. 2022;22:1261&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9303326</ArticleId><ArticleId IdType="pubmed">34910857</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaba A, Johnston T, Aytenfisu T, et al. . A fourth dose of COVID-19 vaccine does not induce neutralization of the Omicron variant among solid organ transplant recipients with suboptimal vaccine response. Transplantation. 2022;106:1440&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213052</ArticleId><ArticleId IdType="pubmed">35417115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>